Electronic Supporting Information

for

Triple-channel lab-on-a-molecule for triple-anion quantification using an iridium(III)-imidazolium conjugate

Kun Chen, Michael Schmittel^{*}

Center for Micro- and Nanochemistry and Engineering, Organische Chemie, Universität Siegen, Adolf-Reichwein-Strasse, D-57068, Siegen, Germany.

Table of Content

Experimental Section	Page 2
General information	Page 2
Synthesis of compounds	Page 4
Preparation of complex 7	Page 5
Preparation of complex 8	Page 5
Preparation of complex 1	Page 6
Preparation of complex 9	Page 7
Preparation of complex 2	Page 8
UV-Vis absorption spectra of complex 1 and 2	Page 10
¹ H NMR spectrum of complex 1 in absence and presence of F^-	Page 10
Deuterium-proton exchange experiment of complex 1	Page 11
Deuterium-proton exchange experiment of complex 2	Page 11
Job plot of complex 1 and F^- in MeCN	Page 12
Competition experiment of complex 1 for F^- in UV-vis channel	Page 12
DPV measurements of complex 1, 2 and 3	Page 13
Titration spectra of complex 2 with $H_2PO_4^-$ in PL channel	Page 13
Calibration curve of complex 2 with $H_2PO_4^-$	Page 14
Job plot of complex 1 and $H_2PO_4^-$ in MeCN	Page 14
Job plot of complex 2 and $H_2PO_4^-$ in MeCN	Page 15
Titration spectra of complex 1 with $H_2PO_4^-$ in UV-vis channel	Page 15
Titration spectra of complex 2 with $H_2PO_4^-$ in UV-vis channel	Page 16

PL spectra of complex 1 in presence of different anions	Page 16
Competition experiment of complex 1 for $H_2PO_4^-$ in PL channel	Page 17
Competition experiment of complex 2 for $H_2PO_4^-$ in PL channel	Page 17
Masking effect of Me ₃ SiCl on F^- for 1 & H ₂ PO ₄ ⁻	Page 18
Masking effect of Me ₃ SiCl on F^- for 2 & H ₂ PO ₄ ⁻	Page 18
¹ H NMR titration of complex 1 with $H_2PO_4^-$	Page 19
¹ H NMR titration of complex 2 with $H_2PO_4^-$	Page 19
DPV measurements of complex 1 in absence and presence of $H_2PO_4^-$	Page 20
DPV measurements of complex 2 in absence and presence of $H_2PO_4^-$	Page 20
Competition experiment of complex 1 for AcO ⁻ in ECL channel	Page 21
General remarks on probe 1	Page 21

Experimental Section

General information

All commercial reagents were used without further purification unless indicated otherwise. ¹H and ¹³C NMR spectra were recorded on a 400 MHz spectrometer at 298 K. Electrospray ionisation mass spectra were recorded using a Thermo-Quest LCQ Deca with ion trap. Elemental analyses were conducted with an EA 3000 CHNS. UV–Vis absorption and PL spectra were recorded on Varian Cary 50 Bio UV–Vis and Varian Cary Eclipse fluorescence spectrometers. Infrared spectra were recorded on a Perkin Elmer 1750 FT-IR spectrometer. Electrochemical measurements were conducted with a Parstat 2273 at room temperature. A conventional three-electrode set-up was used, with a platinum electrode serving as the working electrode, a platinum wire as an auxiliary electrode and a sliver wire as a quasi-reference. DPV measurements were conducted on samples (0.5 mM) dissolved in MeCN with 0.1 M *n*-Bu₄NPF₆ as supporting electrolyte. The scan rate was set at 40 mV/s. Decamethylferrocene (Fc^{*}) was used as internal standard to calibrate the redox potential. Precursors **3**, **4**, 1 **5**² and **6**³ were prepared according to previous work.

ECL measurements were done on the iridium complexes (10 μ M) in MeCN-Tris buffer aqueous solution (9/1, *v*/*v*, 10 mM, pH = 7.2) containing tri-*n*-propylamine (TPrA; 30 mM) as a co-reactant and tetra-*n*-butylammonium hexafluorophosphate (0.05 M) as electrolyte. A standard three-electrode set-up (3.0 mm diameter Pt working electrode, Pt wire auxiliary electrode, and a silver wire as reference electrode) connected to a Princeton Applied Research Model 362 potentialstat was used. To generate the ECL, the potential of the working electrode was swept between 0.7 to 2.0 V (*vs* a silver wire as quasi-reference electrode) at a scan rate *v* = 100 mV s⁻¹. The resulting emission spectra were obtained with a CCD camera cooled to -50 °C (0.500 m Imagining Triple Grating Monochromator/Spectrograph), which was connected to spectrometer Spectrapro 2500i (Acton Research Corporation). The following mechanism is assumed (M = Ir complex)⁴:

$$M - e^{-} \longrightarrow M^{+}$$
 (1)

$$TPrA - e^{-} \rightarrow TPrA^{+}$$
(2)

$$M^{+} + TPrA \longrightarrow M + TPrA^{+}$$
(3)

$$TPrA^{+} \rightarrow TPrA^{+}H^{+}$$
 (4)

$$M^+$$
 + TPrA $\rightarrow M^*$ + TPrA⁺ (side product) (5)

$$M + TPrA' \rightarrow M' + TPrA'$$
 (side product) (6)

$$M^{+} + M^{-} \longrightarrow M^{*} + M \tag{7}$$

Synthesis of compounds



Preparation of 7. Compound 4 (53.6 mg, 50.0 µmol) and 1,10-phenanthroline-4,7-dicarboxaldehyde (23.6 mg, 100 µmol) were dissolved in dichloromethane (15 mL), and the solution was heated to reflux for 5 hrs. After cooling to rt, KPF₆ (55.2 mg, 300 µmol) was added and the mixture stirred for 1 hr. The solvent was removed under reduced pressure and the residue dissolved in dichloromethane. The organic laver was washed with water and dried over Na₂SO₄. The product was purified by column chromatography with dichloromethane/methanol (19/1, v/v) as eluent ($R_f = 0.22$) to afford 7 as a red solid (74.4 mg, 84.5 μmol, 85%). Mp: 204-207 °C (dec.). IR (KBr, cm⁻¹): 3046, 2928, 1705 (C=O), 1608, 1577, 1481, 1419, 1385, 1239, 1114, 1030, 978, 841, 757, 745, 659, 556. ¹H NMR (400 MHz, CD₃CN): δ = 10.62 (s, 11-H, 2H), 9.33 (s, 12-H, 2H), 8.65 (d, J = 5.1 Hz, 9-H, 2H), 8.26 (d, J = 5.1 Hz, 10-H, 2H), 8.08 (ddd, $J_1 = 8.2$ Hz, $J_2 = 1.3$ Hz, $J_3 = 0.7$ Hz, 5-H, 2H), 7.87 (dd, $J_1 = 7.8$ Hz, $J_2 = 1.3$ Hz, 4-H, 2H), 7.81 (ddd, $J_1 = 8.2$ Hz, $J_2 = 7.4$ Hz, $J_3 = 1.5$ Hz, 6-H, 2H), 7.41 (ddd, $J_1 = 5.9$ Hz, $J_2 = 1.5$ Hz, $J_3 = 0.7$ Hz, 8-H, 2H), 7.11 (ddd, $J_1 = 7.8$ Hz, $J_2 = 7.6$ Hz, $J_3 = 1.0$ Hz, 3-H, 2H), 7.00 (ddd, $J_1 = 7.6$ Hz, $J_2 = 7.6$ Hz, $J_2 = 7.6$ Hz, $J_3 = 1.0$ Hz, $J_2 = 7.6$ Hz, $J_2 = 7.6$ Hz, $J_2 = 7.6$ Hz, $J_3 = 1.0$ Hz, $J_4 = 7.6$ Hz, $J_5 = 7.6$ H 7.4 Hz, $J_3 = 1.3$ Hz, 2-H, 2H), 6.86 (ddd, $J_1 = 7.4$ Hz, $J_2 = 5.9$ Hz, $J_3 = 1.3$ Hz, 7-H, 2H), 6.36 (ddd, $J_1 = 7.4$ Hz, $J_2 = 1.0$ Hz, $J_3 = 0.7$ Hz, 1-H, 2H); ¹³C NMR (100 MHz, CD_3CN): $\delta = 193.0, 168.2, 153.8, 150.6, 150.2, 148.7, 145.1, 139.8, 138.7, 132.6, 131.5, 139.8, 138.7, 132.6, 131.5, 139.8, 138.7, 139.8, 139.8, 138.7, 139.8,$ 131.3, 129.1, 127.6, 126.0, 124.5, 124.0, 121.0. ESI-MS $(C_{36}H_{24}IrN_4O_2)^+$: Calcd: m/z = 736.8, found: 737.6. Anal. for C₃₆H₂₄F₆IrN₄O₂P•0.2CH₂Cl₂: Calcd: C, 48.38; H, 2.74; N, 6.23; found: C, 48.31; H, 2.67; N, 6.21.



Preparation of 8. Dicarbaldehyde 7 (44.1 mg, 50.0 µmol) and NaBH₄ (7.57 mg, 200 µmol) were mixed in ethanol (25 mL) under N_2 . The solution was stirred for 1 h at room temperature and solvent removed under reduced pressure. The residue was quenched by water (50 mL) and extracted by dichloromethane (3×25 mL). The organic layers were combined and dried over Na₂SO₄ for 2 h. After filtering off the salt, the filtrate was evaporated to dryness and residue redissolved in dry dichloromethane (20 mL). PBr₃ (9.49 μ L, 100 µmol) was added to the solution under N₂ and the solution was stirred for 4 h at room temperature. Thereafter, the reaction was quenched by water (15 mL) and the aqueous layer extracted by dichloromethane (2 \times 15 mL). KPF₆ (55.2 mg, 300 μ mol) was added to the combined organic solution and the mixture stirred for 1 h. After filtering off the salt, the filtrate was evaporated and the residue purified by column chromatography with dichloromethane/methanol (19/1, v/v) as eluent ($R_f = 0.52$) to afford product 8 as yellow solid (38.4 mg, 38.0 µmol, 76%). Mp: 209-213 °C (dec.). IR (KBr, cm⁻¹): 3042, 1606, 1577, 1475, 1442, 1328, 1241, 1149, 1061, 1032, 841, 756, 728, 557. ¹H NMR (400 MHz, CD_2Cl_2): $\delta = 8.53$ (s, 12-H, 2H), 8.32 (d, J = 5.2 Hz, 9-H, 2H), 7.96 (ddd, $J_1 = 8.3$ Hz, J_2 =1.4 Hz, *J*₃ = 0.8 Hz, 5-H, 2H), 7.81 (d, *J* = 5.2 Hz, 10-H, 2H), 7.76 (ddd, *J*₁ = 8.3 Hz, *J*₂ = 7.6 Hz, J_3 = 1.2 Hz, 6-H, 2H), 7.74 (dd, J_1 = 7.6 Hz, J_2 = 1.2 Hz, 4-H, 2H), 7.35 (ddd,

 $J_{I} = 5.9$ Hz, $J_{2} = 1.2$ Hz, $J_{3} = 0.8$ Hz, 8-H, 2H), 7.11 (ddd, $J_{I} = 7.6$ Hz, $J_{2} = 7.4$ Hz, $J_{3} = 1.2$ Hz, 3-H, 2H), 6.99 (ddd, $J_{I} = 7.6$ Hz, $J_{2} = 7.4$ Hz, $J_{3} = 1.2$ Hz, 2-H, 2H), 6.90 (ddd, $J_{I} = 7.6$ Hz, $J_{2} = 5.9$ Hz, $J_{3} = 1.4$ Hz, 7-H, 2H), 6.39 (ddd, $J_{I} = 7.6$ Hz, $J_{2} = 1.2$ Hz, 1-H, 2H), 5.08 (d, J=11.1 Hz, 11-H, 2H), 5.00 (d, J=11.1 Hz, 11-H, 2H); ¹³C NMR (100 MHz, CD₂Cl₂): $\delta = 168.0$, 151.8, 149.6, 149.1, 147.8, 146.6, 144.2, 138.7, 132.1, 131.1, 130.1, 127.5, 125.3, 125.1, 123.8, 123.3, 120.2, 27.3. ESI-MS (C₃₆H₂₆IrN₄)⁺: Calcd: m/z = 866.6, found: 867.2. Anal. for C₃₆H₂₆Br₂F₆IrN₄P: Calcd: C, 42.74; H, 2.59; N, 5.54; found: C, 42.80; H, 2.45; N, 5.77.



Preparation of **1**. The dibromide **8** (30.3 mg, 30.0 µmol) and 1-(*n*-butyl)imidazole (15.7 µL, 120 µmol) were dissolved in dry acetonitrile (25 mL) under N₂ and the solution heated to reflux for 12 h. After removal of the solvent, the residue was triturated with diethyl ether (50 mL) and solid collected by filtration. After dissolving the solid in dichloromethane, KPF₆ (27.6 mg, 150 µmol) was added and the mixture stirred for 1 h. The salts were filtered off. Product **1** was obtained as orange solid (36.3 mg, 26.1 µmol, 87%) from the filtrate after evapourating the solvent. Mp: 178-180 °C (dec.). IR (KBr, cm⁻¹): 3444 (C2–H), 3168, 2963, 1610, 1580, 1479, 1422, 1257, 1165, 1032, 843, 760, 628, 558. ¹H NMR (400 MHz, CD₂Cl₂): δ = 8.66 (t, *J* = 1.5 Hz, c-H, 2H), 8.39 (d, *J* = 5.3 Hz, 9-H, 2H), 8.38 (s, 12-H, 2H), 7.92 (ddd, *J*_I = 8.3 Hz, *J*₂ = 1.4 Hz, *J*₃ = 0.7 Hz, 5-H, 2H), 7.74 (dd, *J*_I = 7.9 Hz, *J*₂ = 1.1 Hz, 4-H, 2H), 7.71 (ddd, *J*_I = 8.3 Hz, *J*₂ = 7.6 Hz, *J*₃ = 1.4 Hz,

6-H, 2H), 7.52 (dd, $J_I = 1.8$ Hz, $J_2 = 1.5$ Hz, a-/b-H, 2H), 7.47 (d, J = 5.3 Hz, 10-H, 2H), 7.40 (ddd, $J_I = 5.9$ Hz, $J_2 = 1.4$ Hz, $J_3 = 0.7$ Hz, 8-H, 2H), 7.33 (dd, $J_I = 1.8$ Hz, $J_2 = 1.5$ Hz, b/a-H, 2H), 7.08 (ddd, $J_I = 7.9$ Hz, $J_2 = 7.7$ Hz, $J_3 = 1.1$ Hz, 3-H, 2H), 6.96 (ddd, $J_I = 7.7$ Hz, $J_2 = 7.6$ Hz, $J_3 = 1.1$ Hz, 2-H, 2H), 6.92 (ddd, $J_I = 7.6$ Hz. $J_2 = 5.9$ Hz, $J_3 = 1.4$ Hz, 7-H, 2H), 6.37 (dd, $J_I = 7.6$ Hz, $J_2 = 1.1$ Hz, 1-H, 2H), 6.11 (d, J = 16.4 Hz, 11-H, 2H), 6.04 (d, J = 16.4 Hz, 11-H, 2H), 4.20-4.11 (m, d-H, 4H), 1.89-1.80 (m, e-H, 4H), 1.35 (m, f-H, 4H), 0.93 (t, J = 7.4 Hz, g-H, 6H) ppm. ¹³C NMR (100 MHz, CD₂Cl₂): $\delta = 167.6$, 152.3, 149.8, 149.3, 147.7, 144.3, 141.7, 138.6, 136.5, 132.1, 131.0, 129.7, 126.3, 125.2, 124.9, 124.2, 123.6, 123.3 (2C; C3 and Cb), 120.0, 50.9, 49.9, 32.0, 19.8, 13.4 ppm. ESI-MS (C₅₀H₅₀IrN₈•2PF₆)⁺: Calcd: m/z = 1245.1; found: 1245.3. Anal. for C₅₀H₅₀F₁₈IrN₈P₃: Calcd: C, 43.20; H, 3.63; N, 8.06; found: C, 42.82; H, 3.46; N, 7.87.



Preparation of **9**. Dicarbaldehyde **5** (44.1 mg, 50.0 μ mol), NaBH₄ (7.57 mg, 200 μ mol) and ethanol (25 mL) were stirred under N₂ for 1 h at rt, then the solvent was removed under reduced pressure. The residue was quenched by addition of water (50 mL) and extracted by dichloromethane (3×25 mL). The organic layers were dried over Na₂SO₄ for 2 h. The salt was filtered off and the filtrate evapourated to dryness. The resultant solid was dissolved in dry dichloromethane (20 mL). PBr₃ (9.49 μ L, 100 μ mol) was added to the solution under N₂, then it was stirred for 4 h at rt. Thereafter, the reaction was

quenched by water (15 mL) and the aqueous layer was extracted by dichloromethane (2 \times 15 mL). KPF₆ (55.2 mg, 300 μ mol) was added to the combined organic layers and the mixture stirred for 1 h. The salts were filtered off and the concentrated filtrate was purified by column chromatography with dichloromethane/methanol (19/1, v/v) as eluent ($R_{\rm f}$ = 0.46) to afford product 9 as yellow solid (38.7 mg, 38.3 μ mol, 77%). Mp: 175-178 °C (dec.). IR (KBr, cm⁻¹): 3065, 2924, 1590, 1477, 1425, 1310, 1225, 1010, 842, 779, 723, 640, 556. ¹H NMR (400 MHz, CD₂Cl₂): δ = 8.65 (dd, J_1 = 8.3 Hz, J_2 = 1.4 Hz, 10-H, 2H), 1.3 Hz, $J_3 = 0.7$ Hz, 4-H, 2H), 7.85 (dd, $J_1 = 8.3$ Hz, $J_2 = 5.1$ Hz, 9-H, 2H), 7.80-7.74 (m, 3-H, 5-H, 4H), 7.33 (ddd, $J_1 = 5.9$ Hz, $J_2 = 1.4$ Hz, $J_3 = 0.7$ Hz, 7-H, 2H), 7.21 (dd, $J_1 = 5.9$ Hz, $J_2 = 1.4$ Hz, $J_3 = 0.7$ Hz, 7-H, 2H), 7.21 (dd, $J_1 = 5.9$ Hz, $J_2 = 1.4$ Hz, $J_3 = 0.7$ Hz, 7-H, 2H), 7.21 (dd, $J_1 = 5.9$ Hz, $J_2 = 1.4$ Hz, $J_3 = 0.7$ Hz, 7-H, 2H), 7.21 (dd, $J_1 = 5.9$ Hz, $J_2 = 1.4$ Hz, $J_3 = 0.7$ Hz, 7-H, 2H), 7.21 (dd, $J_1 = 5.9$ Hz, $J_2 = 1.4$ Hz, $J_3 = 0.7$ Hz, 7-H, 2H), 7.21 (dd, $J_1 = 5.9$ Hz, $J_2 = 1.4$ Hz, $J_3 = 0.7$ Hz, 7-H, 2H), 7.21 (dd, $J_1 = 5.9$ Hz, $J_2 = 1.4$ Hz, $J_3 = 0.7$ Hz, 7-H, 2H), 7.21 (dd, $J_1 = 5.9$ Hz, $J_2 = 1.4$ Hz, $J_3 = 0.7$ Hz, $T_2 = 0.7$ Hz, $T_3 = 0.7$ Hz, $T_$ 8.1 Hz, $J_2 = 1.7$ Hz, 2-H, 2H), 6.89 (ddd, $J_1 = 7.3$ Hz, $J_2 = 5.9$ Hz, $J_3 = 1.3$ Hz, 6-H, 2H), 6.38 (d, J = 1.7 Hz, 1-H, 2H), 4.35 (d, J = 10.2 Hz, 12-H, 2H), 4.32 (d, J = 10.2 Hz, 12-H, 2H); ¹³C NMR (100 MHz, CD₂Cl₂): $\delta = 167.4$, 151.6, 149.6, 149.0, 147.1, 144.5, 140.6, 139.1, 138.9, 132.3, 132.0, 128.9, 127.2, 125.6, 124.5, 124.0, 120.6, 34.3. ESI-MS $(C_{36}H_{26}IrN_4)^+$: Calcd: m/z = 866.6, found: 867.2. Anal. for $C_{36}H_{26}Br_2F_6IrN_4P^{-1}.5CH_2Cl_2$: Calcd: C, 39.54; H, 2.57; N, 4.92; found: C, 39.40; H, 2.35; N, 4.63.



Preparation of **2**. Dibromide **9** (30.3 mg, 30.0 μ mol) and 1-(*n*-butyl)imidazole (15.7 μ L, 120 μ mol) in dry acetonitrile (25 mL) were heated to reflux for 12 h under N₂. After

removal of the solvent, the residue was triturated by diethyl ether (50 mL) and the solid collected by filtration. After dissolving it in dichloromethane, KPF₆ (27.6 mg, 150 µmol) was added to the solution and the mixture was stirred for 1 h. The salts were filtered off. Product 2 was obtained as orange solid (35.6 mg, 25.6 µmol, 85%) from the filtrate after removing the solvent. Mp: 159-161 °C (dec.). IR (KBr, cm⁻¹): 3438 (C2–H), 3161, 2962, 2870, 1608, 1565, 1478, 1435, 1402, 1339, 1257, 1164, 1064, 843, 752, 632, 558. ¹H NMR (400 MHz, CD₂Cl₂): δ = 8.57 (t, J = 1.5 Hz, c-H, 2H), 8.56 (dd, J_1 = 8.3 Hz, J_2 = 1.4 Hz, 10-H, 2H), 8.36 (dd, J₁ = 5.1 Hz, J₂ = 1.4 Hz, 8-H, 2H), 8.14 (s, 11-H, 2H), 7.96 $(dd, J_1 = 8.3 Hz, J_2 = 1.2 Hz, 4-H, 2H), 7.90 (dd, J_1 = 8.3 Hz, J_2 = 5.1 Hz, 9-H, 1H),$ 7.80 (d, J = 8.1 Hz, 3-H, 2H), 7.76 (ddd, $J_1 = 8.3$ Hz, $J_2 = 7.9$ Hz, $J_3 = 1.4$ Hz, 5-H, 2H), 7.42 (ddd, $J_1 = 5.7$ Hz, $J_2 = 1.4$ Hz, $J_3 = 0.7$ Hz, 7-H, 2H), 7.28 (dd, $J_1 = 1.8$ Hz, $J_2 = 1.5$ Hz, a or b-H, 2H), 7.20 (dd, $J_1 = 1.8$ Hz, $J_2 = 1.5$ Hz, a or b-H, 2H), 6.98-6.91 (m, 2-H, 6-H, 4H), 6.23 (d, J = 1.7 Hz, 1-H, 2H), 5.22 (d, J = 15.1 Hz, 12-H, 2H), 5.10 (d, J =15.1 Hz, 12-H, 2H), 4.14 (t, J = 7.4 Hz, d-H, 4H), 1.90-1.79 (m, e-H, 4H), 1.36 (m, f-H, 4H), 0.97 (t, J = 7.4 Hz, g-H, 6H). ¹³C NMR (100 MHz, CD₂Cl₂): $\delta = 166.8$, 152.6, 150.6, 149.8, 147.0, 145.5, 138.9, 138.6, 135.9, 135.1, 131.7, 131.4, 128.6, 127.8, 125.7, 124.7, 123.3, 122.9, 122.5, 120.5, 53.8 (partly obscured by solvent signal), 50.5, 32.3, 19.8, 13.5. ESI-MS $(C_{50}H_{50}IrN_8 \cdot 2PF_6)^+$: Calcd: m/z = 1245.1, found: 1245.3. Anal. for C₅₀H₅₀F₁₈IrN₈P₃•0.2CH₂Cl₂: Calcd.: C, 43.02; H, 3.62; N, 8.01; found: C, 42.74; H, 3.64; N, 7.82.

Figures and Tables



Figure S1 UV-Vis absorption spectra of complexes 1 and 2 in MeCN; $[1] = [2] = 10 \mu$ M.



Figure S2 ¹H NMR spectra of complex **1** (1 mM) in CD₃CN in (a) absence and (b) presence of 2.8 equiv. of n-Bu₄NF.



Figure S3 ¹H NMR spectrum of complex 1 (1 mM) in CD₃CN/CD₃OD (v/v, 9:1) in (a) absence and (b) presence of 2.0 equiv. of *n*-Bu₄NF.



Figure S4 ¹H NMR spectrum of complex **2** (1 mM) in CD₃CN/CD₃OD (v/v, 9:1) in (a) absence and (b) presence of 2.0 equiv. of *n*-Bu₄NF.



Figure S5 Job plot (Δ Absorbance at 457 nm) of compound 1 vs. F⁻ in MeCN. Concentration: [F⁻] + [1] = 10 μ M.



Figure S6 Absorbance (at 457 nm) of complex 1 (10 μ M) and 50 μ M of F⁻ in MeCN in presence of various anions at $c = 50 \ \mu$ M (0: no additive; 1: NO₃⁻; 2: PF₆⁻; 3: ClO₄⁻; 4: BF₄⁻; 5: Br⁻; 6: MeSO₃⁻; 7: CF₃SO₃⁻; 8: Cl⁻; 9: TsO⁻; 10: PhCOO⁻; 11: AcO⁻; 12: H₂PO₄⁻; 13: HSO₄⁻).



Figure S7 Differential pulse voltammetry (DPV) measurements of complex 1 (green), 2 (red) and 3 (black), all recorded in MeCN with 0.1 M n-Bu₄NPF₆ as electrolyte, Fc^{*} = decamethylferrocene as reference).



Figure S8 PL spectra ($\lambda_{ex} = 272 \text{ nm}$) of complex **2** (10 µM) in presence of H₂PO₄⁻ (0 to 36 µM) in MeCN.



Figure S9 PL titration curve ($\lambda_{ex} = 272 \text{ nm}$, $\lambda_{em} = 566 \text{ nm}$) of **2** (10 µM) in presence of H₂PO₄⁻ (0 to 36 µM) in MeCN.



Figure S10 Job plot (Δ PL at 607 nm) of compound **1** vs. H₂PO₄⁻ in MeCN. Concentrations: [H₂PO₄⁻] + [**1**] = 10 μ M, $\lambda_{ex} = 272$ nm.



Figure S11 Job plot (Δ PL at 566 nm) of compound **2** vs. H₂PO₄⁻ in MeCN. Concentrations: [H₂PO₄⁻] + [**2**] = 10 μ M, $\lambda_{ex} = 272$ nm.



Figure S12 UV-vis absorption spectra of complex 1 (10 μ M) in MeCN during a titration with H₂PO₄⁻ (0 to 30 μ M).



Figure S13 UV-vis absorption spectra of complex 2 (10 μ M) in MeCN during a titration with H₂PO₄⁻ (0 to 30 μ M).



Figure S14 PL spectra ($\lambda_{ex} = 272 \text{ nm}$) of complex **1** (10 µM) in presence of various anions at c = 50 µM (H₂PO₄⁻, HSO₄⁻, F⁻, Cl⁻, Br⁻, BF₄⁻, PF₆⁻, ClO₄⁻, NO₃⁻, CF₃SO₃⁻, MeSO₃⁻, AcO⁻, PhCOO⁻ and TsO⁻).



Figure S15 PL intensity ($\lambda_{ex} = 272 \text{ nm}$, $\lambda_{em} = 607 \text{ nm}$) of complex **1** (10 µM) in presence of 50 µM H₂PO₄⁻ in MeCN and of various anions at *c* = 50 µM (0: no additive; 1: F⁻; 2: Cl⁻; 3: Br⁻; 4: MeSO₃⁻; 5: ClO₄⁻; 6: PF₆⁻; 7: BF₄⁻; 8: AcO⁻; 9: NO₃⁻; 10: PhCOO⁻; 11: TsO⁻; 12: CF₃SO₃⁻; 13: HSO₄⁻).



Figure S16 PL intensity ($\lambda_{ex} = 272 \text{ nm}$, $\lambda_{em} = 566 \text{ nm}$) of complex **2** (10 µM) in presence of 50 µM H₂PO₄⁻ in MeCN and of various anions at $c = 50 \mu$ M (0: no additive; 1: F⁻; 2: Cl⁻; 3: Br⁻; 4: MeSO₃⁻; 5: ClO₄⁻; 6: PF₆⁻; 7: BF₄⁻; 8: AcO⁻; 9: NO₃⁻; 10: PhCOO⁻; 11: TsO⁻; 12: CF₃SO₃⁻; 13: HSO₄⁻).



Figure S17 PL spectra ($\lambda_{ex} = 272 \text{ nm}$) of complex 1 (10 µM) (blue), 1 (10 µM) + 2 equiv. of H₂PO₄⁻ (green), 1 (10 µM) + 2 equiv. of H₂PO₄⁻ and F⁻ (red), 1 (10 µM) + 2 equiv. of H₂PO₄⁻, F⁻ and Me₃SiCl (black).



Figure S18 PL spectra ($\lambda_{ex} = 272 \text{ nm}$) of complex **2** (10 µM) (blue), **2** (10 µM) + 2 equiv. of H₂PO₄⁻ (green), **2** (10 µM) + 5 equiv. of H₂PO₄⁻ and F⁻ (red), **2** (10 µM) + 5 equiv. of H₂PO₄⁻, F⁻ and Me₃SiCl (black).



Figure S19 ¹H NMR spectrum of complex 1 (1 mM) in CD₃CN: (a) in absence and (b) presence of 0.8 equiv, (c) 1.6 equiv, (d) 2.4 equiv of n-Bu₄NH₂PO₄.



Figure S20 ¹H NMR spectrum of complex **2** (1 mM) in CD₃CN: (a) in absence and (b) presence of 0.8 equiv, (c) 1.6 equiv, (d) 2.4 equiv of n-Bu₄NH₂PO₄.



Figure S21 Differential pulse voltammetry (DPV) measurements of complex 1 in the absence (black) and presence (red) of $H_2PO_4^-$ in MeCN (0.1 M *n*-Bu₄NPF₆ as electrolyte, Fc^{*} = decamethylferrocene as reference).



Figure S22 Differential pulse voltammetry (DPV) measurements of complex 2 in the absence (black) and presence (red) of $H_2PO_4^-$ in MeCN (0.1 M *n*-Bu₄NPF₆ as electrolyte, Fc^{*} = decamethylferrocene as reference).



Figure S23 ECL intensity ($\lambda_{em} = 605 \text{ nm}$) of complex **1** (10 µM) in presence of 2 mM AcO⁻ in MeCN-Tris buffered solution (v/v, 9:1, 10 mM, pH = 7.2) and of equimolar amounts of various anions (0: only AcO⁻; 1: F⁻; 2: Cl⁻; 3: Br⁻; 4: MeSO₃⁻; 5: ClO₄⁻; 6: PF₆⁻; 7: BF₄⁻; 8: H₂PO₄⁻; 9: NO₃⁻; 10: TsO⁻; 11: CF₃SO₃⁻; 12: HSO₄⁻; 13: PhCOO⁻).

General remarks on probe 1

Our triple-channel lab-on-a-molecule for three different anions operates on a very fine balance of deprotonation, electrostatic interaction and hydrogen bonding for sensing. Addition of H⁺ will undermine this balance. When the molar ratio of F⁻ (20 μ M) and H⁺ (10 μ M) reaches 2:1 in a MeCN solution of complex **1** (10 μ M), the extra peak at 457 nm in the UV-Vis channel disappears. Similarly, when the molar ratio of H₂PO₄⁻ (30 μ M) and H⁺ (60 μ M) reaches 1:2 in a solution of complex **1** (10 μ M), the enhancement in the PL channel disappears. In case of AcO⁻ (1 mM), H⁺ (up to 100 μ M) did not affect the response of complex **1** (10 μ M) due to the added buffer.

References

- 2 K. K.-W. Lo, C.-K. Chung and N. Zhu, *Chem. Eur. J.*, 2003, **9**, 475-483.
- 3 S. Khatua, D. Samanta, J. W. Bats and M. Schmittel, *Inorg. Chem.*, 2012, **51**, 7075–7086.
- 4 A. J. Bard, ed. *Electrogenerated Chemiluminescence*, Marcel Dekker, Inc., New York 2004.

¹ M. Schmittel and H. Lin, Inorg. Chem., 2007, 46, 9139–9145.